There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Outlook Therapeutics (OTLK – Research Report) with bullish sentiments.
Karyopharm Therapeutics (KPTI)
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Karyopharm Therapeutics, with a price target of $5.00. The company’s shares closed last Thursday at $0.76, close to its 52-week low of $0.75.
According to TipRanks.com, Raymond is a 3-star analyst with an average return of
Currently, the analyst consensus on Karyopharm Therapeutics is a Moderate Buy with an average price target of $6.60, which is a 724.8% upside from current levels. In a report issued on October 30, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Outlook Therapeutics (OTLK)
Outlook Therapeutics received a Buy rating and a $2.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Thursday at $0.34, close to its 52-week low of $0.20.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Outlook Therapeutics with a $1.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KPTI:
